AUSTEDO was studied in a patient population with a range of psychiatric and other comorbid conditions1,2

Efficacy and safety were evaluated in adult patients with tardive dyskinesia (TD) ages 21 to 812,3

Underlying psychiatric conditions in the pivotal study1

AUSTEDO was studied in a patient population with a range of underlying psychiatric conditions: 19% depression, 50% schizophrenia, 10% schizoaffective disorder, 17% bipolar disorder, and 4% other.

Other comorbid conditions2

  • Gastrointestinal disorders
  • Cardiovascular disorders
  • Metabolism/nutritional disorders, including diabetes
  • Lipid disorders

98% of patients were taking at least 1 concomitant medication, including2:

  • Antidepressants at baseline: 54% of patients2
  • Antipsychotics1
  • Atypical: 62% of patients
  • Typical or combination: 14% of patients
  • None at baseline: 24% of patients
Faces of Tardive Dyskinesia (TD) Icon

Patient case studies

Watch: Brian

A patient with bipolar disorder, who has had his routine disrupted by TD play-circle.svg play-circle-active.svg

Watch: Patricia

A patient with major depressive disorder, who is also taking an antihypertensive play-circle.svg play-circle-active.svg

REFERENCES: 1. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604. 2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. 3. AUSTEDO® XR (deutetrabenazine) extended-release tablets and AUSTEDO® current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.